康辰药业
(603590)
| 流通市值：72.48亿 | | | 总市值：73.00亿 |
| 流通股本：1.58亿 | | | 总股本：1.59亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 307,862,872.04 | 366,314,713.38 | 212,131,620.11 | 189,977,701.84 |
| 交易性金融资产 | 481,357,458.29 | 391,050,361.08 | 390,849,333.32 | 450,662,375.93 |
| 应收票据及应收账款 | 320,215,399.29 | 345,252,441.13 | 302,722,762.67 | 251,013,321.48 |
| 应收账款 | 320,215,399.29 | 345,252,441.13 | 302,722,762.67 | 251,013,321.48 |
| 应收款项融资 | 4,545,270 | 4,275,154.97 | 4,328,518.6 | 6,363,288 |
| 预付款项 | 16,193,704.28 | 11,889,335.14 | 9,745,892.9 | 4,712,451.02 |
| 其他应收款合计 | 32,370,406.59 | 32,803,577.54 | 33,796,598 | 33,841,304.86 |
| 存货 | 59,295,393.08 | 69,521,027.12 | 69,870,047.21 | 72,383,172.34 |
| 其他流动资产 | 129,860,067.6 | 156,443,276.99 | 168,930,402.25 | 77,586,421.58 |
| 流动资产合计 | 1,351,700,571.17 | 1,377,549,887.35 | 1,192,375,175.06 | 1,086,540,037.05 |
| 非流动资产: | | | | |
| 长期股权投资 | 404,575,579.96 | 48,610,808.32 | 49,141,244.08 | 49,322,264.29 |
| 其他权益工具投资 | 527,111,409.35 | 696,604,008.15 | 703,359,892.89 | 748,399,124.49 |
| 其他非流动金融资产 | 88,370,621.84 | 88,253,178.36 | 88,083,749.01 | 88,804,516.55 |
| 固定资产 | 320,457,931.75 | 191,098,987 | 193,589,225.97 | 199,173,514.04 |
| 在建工程 | 82,133,203.49 | 216,114,155.24 | 217,857,179.85 | 209,845,880.18 |
| 生产性生物资产 | 325,000 | 362,500 | 400,000 | 437,500 |
| 使用权资产 | 10,948,726.92 | 12,536,449.42 | 15,531,822.78 | 17,275,950.94 |
| 无形资产 | 835,533,644.65 | 838,008,635.73 | 840,040,613.57 | 842,667,929.51 |
| 开发支出 | 288,187,934.67 | 263,629,184.63 | 248,557,598.83 | 233,770,135.29 |
| 长期待摊费用 | 443,086.89 | 495,378.32 | 547,669.74 | 587,961.17 |
| 递延所得税资产 | 21,464,424.1 | 21,806,951.78 | 24,766,826.49 | 27,465,038.74 |
| 其他非流动资产 | 117,304,600.68 | 116,745,575.43 | 310,917,356.75 | 415,399,038.2 |
| 非流动资产合计 | 2,696,856,164.3 | 2,494,265,812.38 | 2,692,793,179.96 | 2,833,148,853.4 |
| 资产总计 | 4,048,556,735.47 | 3,871,815,699.73 | 3,885,168,355.02 | 3,919,688,890.45 |
| 流动负债: | | | | |
| 短期借款 | 211,050,281.36 | 182,390,695.81 | 159,739,719.5 | 140,955,196.27 |
| 应付票据及应付账款 | 52,761,246.05 | 51,592,173.07 | 51,283,103.87 | 73,569,212.75 |
| 应付账款 | 52,761,246.05 | 51,592,173.07 | 51,283,103.87 | 73,569,212.75 |
| 预收款项 | 50,000,000 | - | - | - |
| 合同负债 | 6,574,909.29 | 2,354,059.34 | 3,325,933.91 | 6,426,596.76 |
| 应付职工薪酬 | 35,012,226.25 | 27,962,295.98 | 20,939,151.53 | 43,685,764.1 |
| 应交税费 | 19,314,650.37 | 11,977,452.28 | 7,124,639.31 | 8,880,929.21 |
| 其他应付款合计 | 49,019,744.13 | 48,075,538.8 | 62,192,968.43 | 71,082,843.44 |
| 一年内到期的非流动负债 | 9,191,155.55 | 9,123,866.99 | 8,138,084.09 | 8,071,679.09 |
| 其他流动负债 | 106,612.67 | 47,380.12 | 21,561.17 | 10,993.64 |
| 流动负债合计 | 433,030,825.67 | 333,523,462.39 | 312,765,161.81 | 352,683,215.26 |
| 非流动负债: | | | | |
| 长期借款 | 55,305,312 | 55,574,712 | 49,576,409 | 49,845,809 |
| 租赁负债 | 4,880,258.79 | 6,564,008 | 8,980,667.34 | 10,800,404.42 |
| 递延收益 | 37,582,706.77 | 38,623,037.9 | 39,549,246.51 | 40,475,455.14 |
| 递延所得税负债 | 32,631,455.41 | 31,718,308.21 | 34,632,686.75 | 39,720,009.87 |
| 非流动负债合计 | 130,399,732.97 | 132,480,066.11 | 132,739,009.6 | 140,841,678.43 |
| 负债合计 | 563,430,558.64 | 466,003,528.5 | 445,504,171.41 | 493,524,893.69 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 159,356,477 | 159,356,477 | 159,356,477 | 159,356,477 |
| 资本公积 | 952,526,567.1 | 950,547,293.83 | 948,240,986.8 | 944,595,003.46 |
| 减:库存股 | 19,192,990 | 19,192,990 | 35,927,570 | 35,927,570 |
| 其他综合收益 | -17,103,260.12 | -12,230,834.16 | -6,488,332.13 | 31,795,014.73 |
| 盈余公积 | 80,000,000 | 80,000,000 | 80,000,000 | 80,000,000 |
| 未分配利润 | 2,041,365,198.51 | 1,960,291,997.3 | 2,009,090,794.28 | 1,964,593,400.48 |
| 归属于母公司股东权益合计 | 3,196,951,992.49 | 3,118,771,943.97 | 3,154,272,355.95 | 3,144,412,325.67 |
| 少数股东权益 | 288,174,184.34 | 287,040,227.26 | 285,391,827.66 | 281,751,671.09 |
| 股东权益合计 | 3,485,126,176.83 | 3,405,812,171.23 | 3,439,664,183.61 | 3,426,163,996.76 |
| 负债和股东权益合计 | 4,048,556,735.47 | 3,871,815,699.73 | 3,885,168,355.02 | 3,919,688,890.45 |
| 公告日期 | 2025-10-30 | 2025-08-28 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |